I'm not sure if this old news or not but I just read this.
"BTX1204 is a transdermal gel formation for the treatment of atopic dermititis.
Atopic dermatitis (or severe eczema) is a common inflammatory skin disease most commonly seen in children. An estimated 31.6 million people in the United States have symptoms of eczema or eczematous conditions and at least 17.8 million people have symptoms of atopic dermatitis, considered a more severe form of eczema. Atopic dermatitis is characterized by a loss of barrier function, which is the impermeable outer layer of the skin, and skin inflammation.
The endocannabioid system of the skin has a crucial role skin derived sensory phenomena such as pain and itch. The active being studied by Botanix can exert potent analgesic effects by activation of CB1 and/or CB2 receptors in the skin and possibly other receptors at sensory nerve terminals and/or inflammatory cells"